Bangkok--15 Aug--Bayer Holding
Bayer hosted the Asia Pacific Thrombosis Management: Connecting Patient Care 2018 event in Bangkok, Thailand from 28-29 July 2018. More than 200 physicians and renowned experts in the field of cardiovascular medicine from Asia-Pacific, Europe and North America gathered at the Athenee Hotel, Bangkok to identify the best strategies in advancing the management of thromboembolic diseases in the region. The event featured most up-to-date insights on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in addressing patient's unmet medical needs in thrombosis management. A key highlight was its important opportunity in stroke prevention for atrial fibrillation (AF), a heart rhythm disorder that is expected to impact 72 million patients in Asia by 2050. It was established that patient's risk profiles and co-morbidities such as kidney impairment are key in NOAC treatment selection to ensure safe and effective stroke prevention. The best approaches in the interpretation of evidence from randomized controlled trials and real-world studies to establish the safety experience of a NOAC were discussed. The event also covered the unmet need in the treatment of venous thromboembolism and vascular protection. Overall, there was a high engagement level among the participants, attesting to the importance of these insights in advancing treatment decision and patient care in thrombosis management in Asia-Pacific.
Alexander GG Turpie of McMaster University, Canada, Jafna Cox of Dalhousie University, Canada, , Ajay K Kakkar of University College London, UK, Stuart Connolly of McMaster University, Canada, Atul Verma of Southlake Regional Healthcare Center, Canada, and Peter Verhamme of University Hospitals Leuven, Belgium, Assist.professor Khanchit Likittanasombat, M.D, of Mahidol University and Assoc Prof Dilok Piyayotai, M.D, of Thammasat University were among the distinguished faculty presenting on Thrombosis Management topics
About Bayer
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.